这是描述信息
Search
Submit
Cancel
Nanjing RegeneCore Biotech Co.,Ltd
Nanjing RegeneCore Biotech Co.,Ltd

REGENECORE is an innovative start-up company under the YOUNGY Group, advocating science and culture, paying attention to the growth of employees and enterprises, and maintaining human health.

Nanjing RegeneCore Biotech Co.,Ltd
Nanjing RegeneCore Biotech Co.,Ltd

Mature and complete sdAb humanization technology platform, antibody immunogenicity detection technology platform, and high-throughput sdAb screening technology platform.

这是描述信息

Nanjing RegeneCore Biotech Co.,Ltd

Nanjing RegeneCore Biotech Co.,Ltd is established in the Biomedical Valley of National Nanjing Jiangbei New Area, with a research and office base of nearly 4000 square meters. It is one of the first research and development institutions in the field of sdAbs in China. The company's international scientific consulting expert team has rich experience in the research and development of cell therapy products and clinical applications, providing strong guarantees for the precise positioning and success rate of research and development products. The company has mature and leading sdAb screening technology, and conducts in-depth development in multiple application fields based on this technology.

more
company

NEWS

People's Daily Online | Youngy Group Further Expands Business Empire, Venturing into the Life Science and Technology Sector

People's Daily Online | Youngy Group Further Expands Business Empire, Venturing into the Life Science and Technology Sector

Recent continuous announcements from Youngy Group indicate that the biopharmaceutical-related industry will serve as another new growth engine for the group.
Nanjing RegeneCore's RC1416 Injection Demonstrates Positive Results in Asthma Ib Clinical Study, Initiates Phase II Preparations

Nanjing RegeneCore's RC1416 Injection Demonstrates Positive Results in Asthma Ib Clinical Study, Initiates Phase II Preparations

Nanjing RegeneCore's self-developed RC1416 injection has shown promising progress in its Ib phase clinical study for asthma treatment. Interim data indicate favorable efficacy, safety, and tolerability profiles. Based on these positive outcomes, the RegeneCore team has decided to fully initiate preparations for Phase II clinical studies to accelerate RC1416's clinical development.
Nanjing RegeneCore Announces New Breakthrough in Brain-Penetrating Drug Delivery Technology

Nanjing RegeneCore Announces New Breakthrough in Brain-Penetrating Drug Delivery Technology

The blood-brain barrier (BBB) strictly regulates the passage of substances into and out of the central nervous system (CNS), playing a crucial role in preventing harmful substances from entering the brain from the bloodstream. However, it also poses a significant challenge by restricting most drugs from reaching the brain parenchyma, severely limiting the treatment of CNS disorders.

 

Platforms

High throughput sdAb screening technology platform, sdAb humanization technology platform, antibody immunogenicity detection technology platform, biomacromolecule analysis technology platform, antibody drug CMC process development technology platform

TEL:

025-58608860

Address: Room 07 Building 16 Treehouse, No. 73, Tanmi Road, Jiangbei New District, Nanjing

Enterprise email:rjk@regenecore.com

 

这是描述信息

WeChat cooperative consultation

www.300.cn   nanjing   备案号:ICP18030131-1

please try again.